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The original cohort
Prostate Cancer data Base Sweden (PCBaSe) 2.01,2 is based
on linkages of different national health care registers with
the Swedish National Prostate Cancer Register, and con-
tains more than 110 000 registered cases since 1998. It also
includes a selection of two control series of men free of
prostate cancer (PCa) at the time of samples, as well as in-
formation on brothers of men diagnosed with PCa.
What is the reason for the new data
collection?
PCBaSeTraject includes new linkages, so that we cannot
only study primary treatment but also the entire PCa treat-
ment trajectory. Prostate cancer has become a chronic dis-
ease in a large proportion of afflicted men, since its fatality
rate is low, but statistical cure is never attained.3 Thus,
many men with PCa receive multiple subsequent treat-
ments and their treatment trajectory often spans decades.
In PCBaSeTraject, the PCa treatment trajectory is delineated
by use of data on primary treatment in the National
Prostate Cancer Register (NPCR) of Sweden, verified by
data obtained by linkages with the Prescribed Drug
Registry4 (i.e. use of androgen deprivation therapy (ADT))
and the National Patient Registry (i.e. surgical procedures
and hospital admissions). In addition, data were collected
on radiotherapy (RetroRad) from oncology information
systems and local databases at radiotherapy departments
for treatments performed before 2008 (Figure 1).
What will be new areas of research?
Previously all our studies were limited to treatment at time
of diagnosis. The new focus of PCBaSeTraject is to outline
the full treatment trajectory for a nationwide, population-
based cohort of men with PCa. PCBaSeTraject will also con-
tinue to serve as a platform for studies on patterns of
care, outcomes and adverse effects of treatment in post-
authorization surveillance studies.
Who is in the cohort?
PCBaSeTraject focuses specifically on men diagnosed with
PCa between 1992 and 2012 with available information
on their complete treatment trajectory. It is an update of
PCBaSe 3.0, which is already an update of PCBaSe 2.0
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through inclusion of two additional years of follow-up.1,2
However, since the Prescribed Drug Registry started on 1
July 2005,4 ADT prescriptions could only be captured as
of 1 January 2006, allowing for a 6-month run-in period.
Therefore, only men who were alive and living in Sweden
on 1 January 2006 were eligible (n¼ 116 962) for
PCBaSeTraject. We excluded: 6146 men who, according to
the National Prostate Cancer Register (NPCR), received
ADT as primary treatment but had no corresponding filled
prescription; 938 men who had undergone curative treat-
ment according to NPCR, but with no corresponding in-
formation in other registers; 1948 men who had received
ADT according to the Prescribed Drug Registry in the run-
in period (July 2005–January 2006), without ADT as pri-
mary treatment in NPCR and thus unknown date of ADT
initiation; and 1008 men with missing information on
treatment in the NPCR as well as in other registers. A total
of 106 922 men with PCa with complete and coherent in-
formation on treatment were included in the final study
population (Figure 2, Table 1). In addition, a comparison
cohort of PCa-free men matched by birth year and county
of residence was selected from the background population,
as previously described in detail.1
What has been measured?
PCBaSeTraject is designed to capture information on the
treatment trajectory following the order of treatments:
conservative treatment (CT) ! radical prostatectomy !
radiotherapy ! anti-androgens (AA) ! gonadotropin-
releasing hormone (GnRH) agonists, in which any treat-
ment may be omitted.
Information about conservative treatment was collected
from NPCR and the NPCR Follow-up study5 in three cate-
gories (Figure 3): active surveillance [i.e. regular follow-up
with prostate-specific antigen (PSA) testing and repeated
biopsies with the intent to convert to curative treatment if
signs of progression occur]; watchful waiting (i.e. a treat-
ment strategy where ADT is used if symptomatic progres-
sion occurs); and unspecified conservative treatment
PCBaSeTrajectNPCRRT form
RP form
PROM
data
RetroRad Naonal
Paent
Registry
Prescribed
Drug
Registry
Cause
of Death
Registry
Follow-up
Studies
1998-2002
2003-2007
Diagnoscs
form
Work-up
and treatment
form*
sadesunehwnoitamrofnifoecruoStnemtaerT
primary treatment
Source of informaon when used as a subsequent treatment
Conservave therapy NPCR, Follow-up studies Not applicable
Radical prostatectomy NPCR, RPform*, Follow-up study,
Naonal Paent Register
RPform, Follow-up studies, Naonal Paent Register
Radiotherapy NPCR, RTform, Follow-up study, 
RetroRad,
Naonal Paent Register
RTform, Follow-up studies, RetroRad,
Naonal Paent Register
Androgen Deprivaon Therapy NPCR, Prescribed Drug Register Naonal Drug Register, RPform, RTform, Follow-up studies,
RetroRad, Naonal Paent Register
NPCR: Naonal Prostate Cancer Register; PROM: Paent Related Outcome Measures; RT: radiotherapy, RP: radical prostatectomy
* hp://npcr.se/wp-content/uploads/2015/02/Form-2-work-up-and-treatment.pdf
hp://npcr.se/wp-content/uploads/2013/10/Form-1-Diagnoscs.pdf
Figure 1. Overview of registers providing data for PCBaSeTraject. Data files in blue are part of the National Prostate Cancer Register. Registers with
dashed lines are retrospectively collected. Data files in red are held at the Swedish Board of Health and Welfare.
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(CTUNS) which is a mixture of active surveillance and
watchful waiting because the NPCR did not make the dis-
tinction between these two types of conservative treatment
before 2007.5 Men registered in the NPCR with active sur-
veillance were only considered to be on active surveillance
if they met the inclusion criteria from the Study on Active
Monitoring in Sweden (SAMS), i.e. low-risk cancer in men
below age 70.6 Men registered in the NPCR with watchful
waiting, who underwent radical prostatectomy or radio-
therapy within 2 years of diagnosis were reclassified as
curative treatment. Curative treatment initiated more than
2 years after diagnosis, for men originally registered with
watchful waiting, were registered as non-standard proced-
ures. Watchful waiting was reclassified to primary ADT
when GnRH agonists were used less than 2 months after
diagnosis (Figure 3).
NPCR: National Prostate Cancer Register, ADT: androgen deprivation therapy.
Complete follow-up  
1 Jan 2006 – 31 Dec 2012  
(n=116 962) 
Dead/Emigrated before 1/1 
2006 (n=27 256) 
ADT treatment iniated before 
1 Jan 2006 according to NPCR 
without veriﬁed or 
contradicng connuaon 
according to the Drug Registry  
(n=6 146) Complete follow-up and 
complete ADT 
informaon (n=110 816) Unspeciﬁed curave treatment 
iniated before  
1 Jan 2006 according to NPCR 
not veriﬁed in other sources 
(n=23) 
Complete follow-up, 
complete ADT 
informaon, and 
complete curave 
treatment informaon 
(n= 110 793) Unspeciﬁed non curave 
treatment iniated before  
1 Jan 2006 according to NPCR 
(n=915) 
Missing treatment in NPCR 
before 1 Jan 2006  
(n=1 008) 
To study with complete 
treatment and follow-up 
informaon 
(n= 106 922 ) 
Secondary ADT with unknown 
date of iniaon or 
contradicng treatment paths 
 (n=1 948)
Men in PCBaSe 3.0 
diagnosed 1992-2012 
(n=144 218) 
Figure 2. Flow chart of patient selection for PCBaSeTraject.
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Table 1. Characteristics of men with prostate cancer in PCBaSeTraject
Conservative treatment
(n¼ 28 529)
Radical prostatectomy
(n¼ 29 511)
Curative radiation
therapy (n¼ 17 131)
Anti- androgens
(n¼ 5346)
GnRH agonists
(n¼ 26 405)
All study subjects
(n¼ 106 922)
Age, Mean (SD) 71.5 (8.1) 63.0 (6.1) 66.5 (5.9) 75.5 (7.1) 76.7 (8.0) 69.8 (8.9)
Age in years, n (%)
< 65 6273 (22.0) 17932 (60.8) 6474 (37.8) 445 (8.3) 2337 (8.9) 33461 (31.3)
65 74 12267 (43.0) 11144 (37.8) 9639 (56.3) 1893 (35.4) 7584 (28.7) 42527 (39.8)
75–84 8808 (30.9) 418 (1.4) 1014 (5.9) 2606 (48.7) 12777 (48.4) 25623 (24.0)
85þ 1181 (4.1) 17 (0.1) 4 (0.0) 402 (7.5) 3707 (14.0) 5311 (5.0)
Educational level, n (%)
High 6087 (21.3) 9025 (30.6) 4257 (24.8) 1057 (19.8) 3606 (13.7) 24032 (22.5)
Middle 10685 (37.5) 12023 (40.7) 6804 (39.7) 1884 (35.2) 8408 (31.8) 39804 (37.2)
Low 11505 (40.3) 8315 (28.2) 5967 (34.8) 2343 (43.8) 13954 (52.8) 42084 (39.4)
Missing 252 (0.9) 148 (0.5) 103 (0.6) 62 (1.2) 437 (1.7) 1002 (0.9)
Stage group,a n (%)
Low risk 14626 (51.3) 12226 (41.4) 3534 (20.6) 261 (4.9) 502 (1.9) 31149 (29.1)
-Very low riskb 1824 (25.5) 510 (11.6) 93 (7.3) 3 (3.2) 4 (4.0) 2434 (18.7)
-Not very low riskb 4623 (64.5) 3440 (78.3) 1099 (86.1) 81 (87.1) 82 (81.2) 9325 (71.6)
-Low risk UNSb 715 (10.0) 441 (10.0) 85 (6.7) 9 (9.7) 15 (14.9) 1265 (9.7)
Intermediate risk 8086 (28.3) 12020 (40.7) 5772 (33.7) 1108 (20.7) 2351 (8.9) 29337 (27.4)
High risk 3701 (13.0) 3761 (12.7) 6462 (37.7) 2437 (45.6) 8677 (32.9) 25038 (23.4)
Regionally metastatic 450 (1.6) 380 (1.3) 905 (5.3) 850 (15.9) 4455 (16.9) 7040 (6.6)
Distant metastases 237 (0.8) 148 (0.5) 280 (1.6) 643 (12.0) 10289 (39.0) 11597 (10.8)
Missing data 1429 (5.0) 976 (3.3) 178 (1.0) 47 (0.9) 131 (0.5) 2761 (2.6)
GnRH: Gonadotropin Releasing Hormone
aBased on a modification of the guidelines of the National Comprehensive Cancer Network (1): Low risk (T1–2, Gleason score 2–6 and PSA < 10 ng/ml); inter-
mediate risk (T1–2, Gleason score 7 and/or PSA 10 to < 20 ng/ml); High risk (T3 and/or Gleason score 8–10 and/or PSA 20 to < 50 ng/ml); regionally metastatic
disease (T4 and/or N1 and/or PSA 50 to < 100 ng/ml in the absence of distant metastases (M0 or Mx)); distant metastases (M1 and/or PSA¼ 100 ng/ml and
above).
bFor men diagnosed as of 2008.
CTAS according to NPCR 
(n=11 709)
CTWW according to NPCR
(n=4 857)
CTUNS according to NPCR 
(n=12 829)
SAMS criteria 
fulﬁlled 
Yes  
 (n=9 736) 
No  
 (n= 1 973) 
Curave treatment
within 2 years
Yes  
 (n=617) 
No 
 (n=12 556) 
CTAS
(n= 9 736) 
Curave treatment
(n=617)
CTWW
#
(n=12 307)
CTUNS
(n=6 486)
SAMS criteria 
fulﬁlled 
No 
(n=6 343)
Yes  
(n=6 486)
#285 curave treatments performed later than 2 years from diagnosis recorded as non-standard 
procedures according to registered inial CTWW treatment 
GnRH within 2 months
No 
 (n=12 307)
Yes 
 (n=249)
GnRH  
(n=249)
Figure 3. Flow chart of data collection for conservative treatment in PCBaSeTraject.
NPCR: National Prostate Cancer Register, CTWW: watchful waiting, CTAS: active surveillance, CTUNS: Unspecified conservative treatment, SAMS:
Study on Active Monitoring in Sweden.
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Information on curative treatment was collected from
the NPCR, the NPCR Follow-up studies,5 the National
Patient Registry, and RetroRad to define radical prostatec-
tomy and radiotherapy. The majority of primary radical
prostatectomies and radiotherapies registered in NPCR
were verified by data in other registers (Figure 4). A total
of 679 men registered with curative treatment in NPCR,
but with no corresponding treatment in other registers,
and who had received ADT according to the Prescribed
Drug Registry within 9 months of date of diagnosis, were
considered to be treated with primary ADT.
To obtain information on deferred radical prostatec-
tomy following a period of conservative treatment, we
used the NPCR Follow-up study and information from the
Patient Registry (Figure 2). Since 1987, the National
Patient Registry has collected information regarding inpa-
tient care. Each record contains medical information on
surgical procedures, hospital department, and discharge
diagnoses coded according to ICD-9 or ICD-10.2 A com-
mon classification of surgical procedures has been used in
Sweden since 1997.7
To collect information on deferred curative radiother-
apy following a period of conservative treatment or as ad-
juvant/salvage therapy following radical prostatectomy,
we used information from the NPCR, the NPCR Follow-
up study, RetroRad and the National Patient Registry
RP according  
to NPCR 
(n= 27 955) 
RT according  
to NPCR 
(n= 15 268) 
Curave treatment 
without speciﬁcaon 
in NPCR 
(n= 2 530)
RP according to NPCR or 
within 2 years according to 
other registers$
Yes  
  (n= 29 161) 
RP#
(n= 29 161) 
No 
(n= 17 444)
ADT within 
9 months
AA 
  (n=208) 
GnRH 
 (n=471) 
RT&
(n= 16 765)
Yes
 (n=16 765) 
No
 (n=679) 
#RP registered as primary treatment in NPCR for 27 823 men, with NPCR as the only source of treatment evidence for 688 men 
RT according to NPCR or 
within 2 years according 
to other registers£
&
RT registered as primary treatment in NPCR for 14 909 men, with NPCR as the only source of treatment evidence for 491 men.
ADT treatment according to 
NPCR recognised to be curave¤
according to other registers
(n= 852)
¤
Within 2 years from diagnosis
$Inpaent Registry, NPCR Follow-up study 
£
Inpaent Register, NPCR Follow-up study, and RetroRad  
Figure 4. Flow chart of data collection for curative treatment in PCBaSeTraject.
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(Figure 2). In 2008, the NPCR created a specific form to
collect information on radiotherapy (RTForm) (Appendix
A1, available as Supplementary data at IJE online). There
is little information regarding radiotherapy in the National
Patient Registry, although this information has gradually
become more detailed in recent years. To overcome
this lack of information, mainly for the time period
before 2008, a retrospective data collection was
performed (RetroRad). Radiotherapy data were retrieved
from the verification/oncology information systems
and local databases of radiotherapy departments
in Sweden, including information on type of radiotherapy,
treatment dates, total dose and fractionation.
RetroRad captures information from the early 1990s until
2008–12, depending on the availability of databases at
each centre.
Information about primary ADT was collected from the
NPCR, the NPCR Follow-up study,5 the National Patient
Registry and the Prescribed Drug Registry (Figure 2). First,
we assessed whether a prescription had been filled for an
anti-androgen or a GnRH agonist within 3 months after
date of diagnosis. If this was not the case, the treatment
strategy was defined as watchful waiting (Figure 5). Hence,
ADT used as adjuvant or neoadjuvant in combination with
curative treatment was ignored. To distinguish neoadjuvant
and adjuvant ADT from use of ADT due to disease progres-
sion, we retrieved information on ADT from the Prescribed
Drug Registry and compared with information for ADT on
the RTForm and RPForm in the NPCR. ADT given before
curative treatment was considered as neoadjuvant if de-
livered less than 18 months prior to that treatment. If ADT
was initiated more than 18 months prior to curative treat-
ment, it was considered to be primary ADT. With respect
to adjuvant ADT for men who did not have information on
the RTForm or RPForm in the NPCR, use of ADT without a
discontinuation of at least 9 months during the first 3 years
after curative treatment was considered to be adjuvant. For
men receiving curative treatment with no information from
the RTForm or RPForm, dates were retrieved from RetroRAD
or the Patient Registry. Furthermore, a distinction was
required between anti-androgen monotherapy and flare
protection. Anti-androgens initiated less than 3 months be-
fore subsequent GnRH agonists were considered to be flare
protection, whereas other time frames for anti-androgen
AA according to NPCR 
(n=5 137)
GnRH according to NPCR 
(n=25 556)
Unspeciﬁed palliave 
treatment according 
to NPCR (n=229)
AA treatment veriﬁed and not 
combined with GnRH in within 3 
months according to the Drug Registry  
Yes  
 (n=5 138) 
No 
 (n= 25 784) 
Yes  
 (n=25 685) 
No  
 (n=99) 
AA   
(n= 5 138) 
GnRH
(n=25 685)
RP
(n=26)
GnRH treatment veriﬁed in the 
Drug Registry (or surgical 
orchiectomy in the Paent Registry) 
RT
(n=73) 
Curave 
treatment? 
Figure 5. Flow chart of data collection for androgen deprivation therapy in PCBaSeTraject.
NPCR: National Prostate Cancer Register, RP: radical prostatectomy RT: curative radiotherapy, ADT: androgen deprivation therapy, AA: anti-androgen
monotherapy, GnRH: GnRH agonists.
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prescriptions were considered as indicators of anti-andro-
gen monotherapy. Additional treatment information was
obtained from the National Patient Registry, the Prescribed
Drug Registry and the RetroRad (Figure 2).
Follow-up in PCBaSe for data from the Prescribed Drug
Registry, the National Patient Registry and the Cause of
Death Registry are annually updated. All data manage-
ment was conducted with SAS 9.3 (SAS Institute, Cary,
NC), and statistical modelling was performed with
R 2.13.2 (R Foundation for Statistical Computing,
Vienna). The Research Ethics Board at Umea˚ University
Hospital approved the study.
What has it found?
We found that the time to treatment changes was depend-
ent on type of primary treatment and subsequent treat-
ments (Figure 6). For example, men treated with primary
radical prostatectomywere more likely to receive adjuvant
or salvage radiotherapy than men who underwent deferred
prostatectomy after an initial period of active surveillance.
There was also a difference in timing and proportion of
men who received androgen deprivation therapy due to
disease progression after primary or secondary radiother-
apy, as ADT was introduced earlier and to a larger
proportion of men who had received primary
0
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Figure 6. Time to treatment changes based on different primary and subsequent treatments for men with prostate cancer as registered in
PCBaSeTraject.
PCa: prostate cancer, AA: anti-androgen monotherapy, RT: curative radiotherapy, RP: radical prostatectomy.
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radiotherapy. One-third of the men who were registered as
active surveillance had converted to curative treatment 6
years after diagnosis, and most of these men had under-
gone radical prostatectomy (24%) or radiotherapy (12%)
(results not shown). The proportion of men who died of
Pca was higher among those who receivedGnRH agonists
as primary treatment, compared with men who received
GnRH as second-line treatment. Overall,17% of men
received two subsequent treatments and 2% received three
treatments (Table 2).
Figure 7 shows how misclassification of treatment due
to incomplete information may lead to erroneous conclu-
sions. Under the assumption that ADT implies dissemi-
nated PCa, using data from the Prescribed Drug Registry
only would over-estimate the prevalence of disseminated
disease. However, using multiple data sources,
PCBaSeTraject identified men on adjuvant ADT, i.e. com-
bined with radiotherapy, thus avoiding this misclassifica-
tion. Furthermore, combined treatment data in
PCBaSeTraject correctly demonstrated the number of men
with low-risk cancer on GnRH agonists as secondary treat-
ment, who died of PCa, whereas data from the Prescribed
Drug Registry only would have underestimated this
number.
The additional data from PCBaSeTraject have already
allowed us to investigate the association between types and
duration of ADT and risk of cardiovascular disease (CVD)
in greater detail than was previously possible.8 We found
an increased risk of CVD, in particular within the first year
of ADT, which was strongest for men with a previous his-
tory of CVD.
In another study, we investigated long-term complica-
tions for men who were curatively treated with radiother-
apy or radical prostatectomy. We specifically evaluated
urinary incontinence, lower urinary tract symptoms and
gastrointestinal symptoms up to 12 years after treatment.
It was found that these complications mostly occurred
within the first 3 years after radical prostatectomy,
whereas complications after radiotherapy were more fre-
quent at a later date after treatment.9
An overview of all publications based on PCBaSe
Sweden can be found at [www.npcr.se/forskning].
What are the main strengths and
weaknesses?
PCBaSeTraject contains comprehensive data on the treat-
ment trajectory for men with PCa. Our results demonstrate
that both clinical knowledge and ‘register know how’ are
necessary to correctly perform analysis and interpret data
from such register-based studies. PCBaSeTraject showed
high concordance of treatment classification between
different registers. One limitation of PCBaSeTraject is the
lack of information on indications for additional treat-
ment. Continuous registration of PSA levels would be a
useful way to assess disease progression and efforts to ob-
tain such data are under way. Finally, it is worth noting
that due to the later start date of the Prescribed Drug
Registry (1 July 2005), PCBaSeTraject requires use of left-
truncation in all time-to-event analysis.
Can I get hold of the data? Where can I find
out more?
The steering groups of the NPCR and PCBaSe welcome ex-
ternal collaborations. For more information please see
[www.npcr.se/in-english], where registration forms,
Table 2. Treatment trajectories in PCBaSeTraject
Men with one treatment n (%)
CTAS 6609 (6.2)
CTWW 8280 (7.7)
CTUNS 3667 (3.4)
RP 23 252 (21.7)
CurRT 14 525 (13.6)
AA 3534 (3.3)
GnRH 26 405 (24.7)
Men with two treatments
CTAS! RP 1584 (1.5)
CTAS! RT 824 (0.8)
CTAS! AA 271 (0.3)
CTAS! GnRH 186 (0.2)
CTWW! AA 1274 (1.2)
CTWW! GnRH 2402 (2.2)
CTUNS! RP 674 (0.6)
CTUNS! RT 523 (0.5)
CTUNS! AA 495 (0.5)
CTUNS! GnRH 746 (0.7)
RP! RT 3829 (3.6)
RP! AA 720 (0.7)
RP! GnRH 429 (0.4)
CurRT! AA 1065 (1.0)
CurRT! GnRH 1098 (1.0)
AA! GnRH 1812 (1.7)
Men with three treatments
Starting in CT 916 (0.9)
Starting in RP 1077 (1.0)
Starting in RT 443 (0.4)
Men with four treatments
Starting in CT 72 (0.1)
Starting in RP 204 (0.2)
Men with five treatments
Starting in CT 6 (0.0)
CT, conservative treatment; CTWW, watchful waiting; CTAS, active surveil-
lance; CTUNS, unspecified conservative treatment; RP, radical prostatectomy;
RT, curative radiotherapy; AA, anti-androgen monotherapy; GnRH, gonado-
tropin-releasing hormone agonist.
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manuals and annual reports from the NPCR are found as
well as a full list of publications from PCBaSe.
Supplementary Data
Supplementary data are available at IJE online.
PCBaSeTraject: UPDATE IN A NUTSHELL
• PCBaSe Sweden 2.0 was updated to include more
information on the prostate cancer treatment trajec-
tory: PCBaSeTraject.
• Prostate cancer has become a chronic disease in a
large proportion of afflicted men, so that many men
with prostate cancer receive multiple subsequent
treatments and their treatment trajectory often spans
decades. To better delineate the pattern of care and
outcomes, data collection has been enhanced in the
National Prostate Cancer Register (NPCR) of Sweden
and the Prostate Cancer data Base Sweden
(PCBaSe), resulting in PCBaSeTraject.
• This includes a precise delineation of the treatment
trajectory for men with PCa who were alive on 1
January 2006 (n¼106 922). Following primary treat-
ment, a subsequent treatment was initiated in 17932
(17%) of these men and 2436 (2%) men received
three subsequent PCa treatments.
• In addition to linkages to several health care regis-
tries and demographic databases, PCBaSeTraject also
includes data on radiotherapy (RetroRad) from on-
cology information systems and local databases at
radiotherapy departments for treatments performed
before 2008.
• For more new collaborative projects and enquiries
about data sharing, please contact [npcr@npcr.se].
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Figure 7. Time to initiation of GnRH agonists and time to PCa death since time of GnRH agonists initiation for men with prostate cancer, as registered
in PCBaSeTraject.
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